clinical trial · NCT02115165
A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors
Gustave Roussy, Cancer Campus, Grand Paris·phase2·completed·n = 34
Non-seminomatous Germ-cell TumorsCabazitaxel
brief summary
Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing and limited peripheral neuro-toxicity, two major potential advantages in patients with advanced NSGCTs. Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have demonstrated activity in pre-treated GCTs and are now part of standard treatment, but cabazitaxel has not yet been tested in patients with NSGCT.
started
Jul 23, 2014
primary completion
Apr 29, 2022
completion
Apr 24, 2023
last updated
Apr 6, 2026
official title
A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol